Erlotinib for Treatment of Psoriasis
| Status: | Archived |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2011 |
Phase II Randomized, Double-blind, Placebo-controlled, Two-arm Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis
The purpose of this study is to determine whether erlotinib is effective in the treatment of
psoriasis.
Psoriasis vulgaris is a disease that affects 25 million people in North America and Europe.
It often presents in late adolescence and usually persists for life. Current therapies
target specific immune molecules that are implicated in the cause of this disease. For
example, biologic agents that are used in severe psoriasis are aimed at inflammatory
mediators. These therapies have been proven to be effective but also have their limitations.
We found this trial at
1
site
Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
Click here to add this to my saved trials
